Category Archives: Corporate News

Medizone International Announces Agreement Retaining EMA Partners as Advisor and Investment Bank

KALAMAZOO, MICH. March 1, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, the only EPA cleared hospital room disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens, announced today that the Company has entered into a definitive agreement with EMA Partners retaining them as the Company’s advisor for financing and investment banking matters.

In late 2016, AsepticSure was cleared by the US Environmental Protection Agency for entry into the United States market.  The Company has been preparing for entry into a significant market that has a growing need for effective technologies that are capable of breaking the hospital acquired infection cycle.

“We are very pleased to announce that Medizone International has reached an agreement to have EMA Partners serve as our advisor and investment bank. EMA Partners and its elite group of partners and life-science advisors have a remarkable track record of helping to create shareholder value in promising life-science companies,” said David Esposito, Chairman and CEO of Medizone International. “As our team has completed several key milestones in the development of AsepticSure, we are preparing to scale our commercial operations in the United States and beyond.  We look forward to EMA Partners helping us realize the full potential of our business.”

“EMA Partners looks forward to working with the seasoned management team and board at Medizone to explore strategic options  to scale the business and to develop strategic partnerships with a broad range of industry players,” said Andy Raeder, founding partner of EMA Partners. “We believe the AsepticSure technology has the potential to significantly impact the large unmet need of reducing hospital acquired infections.  In addition, we see a large number of other compelling areas where this technology could be deployed to increase value creation for the Company.”

Medizone continues to execute on plans to increase manufacturing, technical service and support, and lead generation channels to secure initial US customers for AsepticSure.  The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 in response to the increased prevalence and awareness of hospital acquired infections.  The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets. With EPA approval in late 2016, the company is now prepared to expand into the U.S. market.

Safe Harbor Statement

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the US and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations

Medizone International, Inc.

T: 01 (269) 202-5020

E: [email protected]

For more information, visit:

www.medizoneint.com

Email: [email protected]

About EMA Partners, LLC

EMA is focused on assisting its clients with mergers, acquisitions, divestitures, intellectual property licensing and sales, recapitalizations, transition planning and other transactional-based services.

We apply a process and perspective well suited to middle market clients across all geographies. With a professional staff of advisors from a variety of business disciplines, we are able to provide the strategy, analytics, marketing and transactional work to meet our clients’ goals across industry verticals. This expertise is reflected in the wide range of transactions EMA has handled, ranging from outright sale of traditional industrial companies to licensing of sophisticated pre-revenue intellectual property.

Our focus has always been on the middle market, and on understanding client companies’ objectives and strengths, communicating those strengths to prospective buyers or partners, and structuring transactions in a manner that maximizes value for our clients.

For more information, visit www.emapartners.com.  Securities -related services provided through Burch & Company, Inc., member FINRA/SIPC.

Medizone Progress Report

South American and US milestone regulatory events achieved
Additional patents granted
Shareholder Meeting delay due to minority shareholder proxy proposals

 

IMG_1778

August 25, 2016

Dear Shareholders,
I would like shareholders to know that management with support from our entire Board of Directors has been working diligently and faithfully to achieve the final steps necessary to see Medizone’s AsepticSure® system achieve not only regulatory approval, but successful US market acceptance.

Regulatory Approvals

Our distribution partners in South America, GYD, S.A. have recently confirmed they have now achieved ISP regulatory approval for AsepticSure into Chile, their first country of entry in S.A. ISP is the Chilean equivalent to EPA. Of the three initial systems purchased by the distributor, two are in their possession and the third is scheduled to be shipped the end of this week.

In the US, the EPA approval process has also been progressing. Cogmedix, Medizone International’s contract manufacturing partner, has obtained EPA company and establishment numbers to serve as a manufacturer for the AsepticSure delivery systems. Cogmedix already held FDA medical device manufacturing status. These numbers allow EPA to track the AsepticSure delivery system from the manufacturer to the user facility and allow Cogmedix to ship AsepticSure systems directly to hospitals in the US. This is an important step closer to market entry in the US.

Medizone’s hydrogen peroxide supplier also has an EPA registration that allows them to ship the product to users.

IMG_1780These recently achieved milestone events signal the beginning of US market entry for AsepticSure. In-hospital trials designed to replicate the success AsepticSure obtained at Trenton Memorial Hospital and Bellville General Hospital in eliminating new HAI cases for significant periods of time from AsepticSure disinfected Isolation rooms, will signal the beginning of what we believe will prove to be the successful commercial ascendance of AsepticSure in the United States. The vastly superior efficacy of AsepticSure over any competing technology, demonstrated in a highly prestigious US hospital, should signal a commercial turning point for AsepticSure leading to product acceptance and profitability for Medizone International.

 

EU Patents

On the patent front, the Company also continues its history of success. The EU patent office has granted our Health Care Patent Application. The Company is now registering coverage under the EU treaty for Germany, France and the United Kingdom. This EU patent grant follows the recent issuance of patent coverage in the EU for our bio-terrorism counter measures application, which has been registered in the same countries.

 

Annual General Meeting of Shareholders

As disclosed by the Company in its current report on Form 8-K as filed with the SEC on August 19, 2016, the Company has moved the scheduled date of its Annual Meeting of Shareholders from September 15th to December 15th.

The Board has established December 15, 2016 as the new date for the Annual Meeting, and established September 30, 2016 as the record date for stockholders entitled to notice of and to vote at the meeting.

The decision to postpone the Annual Meeting follows receipt by the Company of certain stockholder requests to include additional proposals for vote at the meeting. The stockholder proposals were received by the Company after the filing of the Company’s preliminary proxy materials with the SEC, and just prior to the mailing of the Company’s Notice of the Annual Meeting for September 15, 2016.

Pursuant to regulations of the SEC, the Company is corresponding with the stockholder proponents, and with the SEC, regarding the proposals, including with respect to issues of legality of the proposals and the Company’s alternatives for inclusion, exclusion, or revision of the proposals. In light of the proposals received, the postponement of the Annual Meeting is necessary to ensure the Company can meet applicable meeting notice deadlines and allow the Board and the proponents adequate time to evaluate the proposals and correspond with the SEC. While the Company considers the delay caused by the stockholder proposal issues unfortunate, the Company expects to be in a position to file, and mail or post to the Internet, updated proxy materials for the benefit of all Company stockholders, as required, for the December 15, 2016 meeting date.

The Company’s proxy statement filed with the SEC included a request to increase the authorized common stock vault from 395M authorized to 500M authorized in order to be assured there are shares available to secure the capital funding required to complete US market entry, initiate an increase in production and see AsepticSure through as not only the finest room disinfection system in the world, but one that is commercially profitable. Although the meeting originally scheduled on September 15 to consider that proposal has been postponed to December 15, 2016, the Company anticipates that the same proposal to increase its shares of common stock will remain in the proxy materials to be circulated for the December 15 meeting.

Under the business corporation statues of the State of Nevada applicable to the Company, the Company must obtain greater than 50% approval of all issued and outstanding shares in order to amend its Articles of Incorporation to increase the vault. The ability of the Company to fund operations and increase production is considered vital by our management team and Board of Directors. Without an increase in available shares to achieve the necessary funding to achieve these goals, the Company’s options become extremely limited. When a new proxy statement is circulated to the Company’s shareholders in connection with the December 15th meeting, it will still contain this Company proposal for an increase in share authorization to enable the adequate funding of the Company through full commercialization. We strongly urge shareholders to support this increase.

Best regards,

Edwin G. Marshall
Chairman of the Board
Chief Executive Officer

 

This letter contains certain forward-looking statements representing our expectations or beliefs regarding our company. These forward-looking statements include, but are not limited to, statements regarding our business, anticipated financial or operational results and objectives. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” anticipate,” “intend,” “could,” “estimate,” “might,” or “continue” or the negative or other variations thereof are intended to identify forward-looking statements. These statements, by their nature, involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

AsepticSure’s South American Distributor Places Order

San Francisco, California, June 20, 2016: Medizone International, Inc. (OTCQB: MZEI). GYD S.A., Medizone’s exclusive distributor for our AsepticSure® hospital disinfection system in Chile, Brazil, Colombia and Peru, intends to offer both a service model and sales model for AsepticSure distribution. They are leading the regulatory approval process in their Territory. Exclusive distribution rights will be expanded to other countries in South America on a country-by-country basis as GYD S.A. achieves regulatory approvals and establishes channels of distribution.

With regulatory approval progressing, GYD S.A. has placed an initial order for the first three Generation III AsepticSure systems. Delivery is scheduled for early July.

While the roll out of AsepticSure distribution throughout South America will be gradual, the principals of GYD S.A. have been successful twice before using the same business model in establishing distribution channels throughout the continent. Given the acute need to address major hospital based infection issues on the continent, including evidence of super bugs in Rio with the up-coming Olympic Games, the ability to greatly reduce these infection threats in the health care community is gaining attention. Medizone believes GYD S.A.’s proven business model will be successful again.

Only AsepticSure disinfection technology achieves a greater than 6-log (> 99.9999%) kill of all infective pathogensviral or bacterialthroughout the entire room. That is the same FDA standard of disinfection used to sterilize medical instruments in an autoclave. Once a room is disinfected with AsepticSure’s ‘green’ technology, it will remain safe until a new pathogen is introduced from the outside. Medizone has proven that unless 100% of infective pathogens are eliminated from the disinfected space, regrowth will occur and new infections become likely. No other disinfection technology has proven capable of eliminating the source of environmentally caused infections completely; AsepticSure does so with every room cleaning.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: [email protected]

For more information, visit:
http://www.medizoneint.com
Email: [email protected]

AsepticSure Receives EU Patent Approval For its Bio-Terrorism Counter Measures Application

San Francisco, California, June 13, 2016 – Medizone International, Inc. (OTCQB: MZEI) is pleased to announce that its unprecedented room disinfection technology, AsepticSure®, has been granted patent protection by the European Union Patent and Trademark Office (EU) for its patent application Bio-Terrorism Counter Measures Using Ozone and Hydrogen Peroxide. The European Patent Office awarded patent number 252583B to this application, which provides a government counter measures response to a biological attack.

Medizone already has a significant number of applications granted for its disinfection technology for health care and sports facility disinfection. To date, AsepticSure has demonstrated a greater than 6-log kill (>99.9999% kill) against all bacterial and viral pathogens it has been tested against. This EU patent grant expands on the previously awarded bio-terrorism patent protection as awarded in the United States and Canada. With this EU patent, Medizone secures patent protection in the United Kingdom, Germany and France.

Recently, Acinetobacter baumannii, another highly infective pathogen of concern to certain US government interests as well as the government of South Africa, has been defeated by AsepticSure. To date, our AsepticSure technology has defeated every infective pathogen – viral or bacterial – that it has been tested against. Eliminating all infective pathogens from a disinfected space eliminates the infective reservoir, thus rendering the treated space harmless and safe.

This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 415 331-0202
E: [email protected]

For more information, visit:
http://www.medizoneint.com
Email: [email protected]

The AsepticSure® Hospital Disinfection System Introduced to South America

AsepticSure®, the only hospital disinfection system in the world that achieves 100% bactericidal kill, dramatically reducing new rates of hospital acquired infections in the rooms treated, will be distributed in South America by GYD S.A.

asepticsure-aSantiago, Chile and San Francisco, California, November 17, 2015. Medizone International, Inc. (OTCQB:MZEI) or Medizone, manufacturer of the AsepticSure® Hospital Disinfection System, and GYD S.A. today announced that they have entered into an agreement for the introduction and distribution of AsepticSure® in South America (the “Distribution Agreement”). Medizone granted GYD S.A exclusive distribution rights for the AsepticSure® system in Chile, Brazil, Colombia and Peru. GYD S.A. will lead the regulatory approval process throughout South America and exclusive distribution rights will be expanded to other countries in South America on a country-by-country basis as GYD S.A. achieves regulatory approvals and establishes channels of distribution.

GYD S.A. Investment in Medizone International

In connection with the negotiation and execution of the Distribution Agreement, GYD S.A. and three other investors in Chile have invested $1 million in Medizone. The funding included the sale of 10,000,000 shares of Medizone common stock at a price of $0.10 per share. In addition, the investors acquired stock purchase warrants exercisable for one year to purchase an additional $1 million of common stock. The exercise price of the warrant shares is fixed at a 40% discount to market at the time of the exercise, however, in the event the warrants are exercised on or before March 30, 2016, the exercise price per share will be capped at the lesser of 40% discount to market or $0.25 per share. There is a one-year lock up on the shares acquired in the initial stock purchase.

Medizone’s CEO, Edwin Marshall commented, “GYD S.A.’s founder and Chief Executive Officer, Gerardo Guzman Hargous, is a graduate of Pontificia Universidad Catolica and holds an MBA from the University of Chicago. Mr. Hargous has a successful history of starting businesses in Chile and expanding them throughout South America. For example, he is the founder of GMS Productos Gráficos Ltda. (“GMS”), a graphics business in Chile. After building the business successfully for 20 years, in 2003 Mr. Hargous sold GMS to Antalis Group. GMS also had the representation of Fuji S.A. a division of Fuji, Japan. Later, he founded and expanded Best Way Group, a pest control company, which he sold in 2014 to Rentokil Initial plc, traded on the London Stock Exchange. In addition to his entrepreneurial activity in South America, Mr. Hargous also taught options trading at the University of Chile in Santiago.

“In addition to GYD providing Medizone International a single point of contact for regulatory approval and distribution in South America, Mr. Hargous will add to the company’s global strategic strength by assuming an advisory role to our board of directors. Medizone welcomes him as a strategic partner to its global AsepticSure distribution plan,” added Mr. Marshall.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

AsepticSure Update: June 25, 2015

Screenshot 2015-06-24 19.51.36

What has proven to be a long and challenging regulatory journey appears to be approaching its final destination as Medizone has filed what is expected to be its final EPA submission.

What places AsepticSure® in a league by itself lies not only in its ability to achieve remarkable levels of room disinfection within a busy time-sensitive hospital environment, but the fact that it utilizes a new “green” technology that meets all international safety standards without damaging the environment or leaving residual chemicals behind. It achieves this in both a time and cost-effective manner. The fact that AsepticSure comfortably meets the U.S. Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit TWA (PEL-TWA), the American Conference of Governmental Industrial Hygienists (ACGIH®) Threshold Limit Value TWA (TLV®-TWA), and the U.S. Environmental Protection Agency (EPA) National Ambient Air Quality Standards (NAAQS) is noteworthy. The ultimate approval by the EPA as a room disinfectant will bring this system through the gates to continent-wide commercial success. AsepticSure establishes a previously unobtainable level of disinfection efficacy and is proving to be a time efficient technology inside hospital workflows. Data to date demonstrates significantly reduced new infection rates, resulting in economic savings to the medical system through avoidance of the treatment costs associated with hospital acquired infections (HAI).

Working in conjunction with highly experienced regulatory advisors from Washington and Virginia, our team at Innovation Park, Queen’s University believe we have successfully met all of the registration requirements of the agency, including those challenges referred to in the May 6th shareholder communication posted on our website.

EPA now has 21 days to conduct a preliminary review for any possible deficiencies, after which the formal review will commence.

The Canadian National Infection Prevention and Control Conference

The Canadian National Infection Prevention and Control Conference

June 14 – 17 held in Victoria, BC

Dr. Michael Shannon telephoned me this past Monday evening from the dinner sponsored by Medizone in Victoria at the Canadian National Infection Prevention and Control Conference.  Dr. Shannon reported that the two presentations given earlier that day by Dr. Dick Zoutman, the first on AsepticSure’s success in eradicating C.difficile at Trenton Memorial Hospital and the second on the National Research Council Canada’s confirmation of AsepticSure success in defeating viral pathogens, were both exceptionally well received.

The dinner that followed was attended by 21 senior leaders in infection control from across Canada and in keeping with the Conference theme, “Surfing the Waves of Change”, AsepticSure® was presented as a potential tsunami in the battle against Hospital Acquired Infection.

Senior infection control experts from provincial ministries, hospitals, provincial ambulance organizations and several well-known universities were present.  

Drs. Michael Shannon and Dick Zoutman both spoke at the dinner.  Never before have so many key health care professionals gathered in the same room to learn about the breakthroughs AsepticSure continues to demonstrate.

We are convinced that AsepticSure is creating, what Thomas Kuhn in his book, The Structure of Scientific Revolutions, described as a paradigm shift in scientific understanding. In this instance, revolutionizing the understanding of what is possible in hospital disinfection. Like all other “disruptive innovations”, a tidal wave of associated changes must be accepted as new systems and approaches take hold to realize the overall goal of a safer pathogen free hospital environment.

Until very recently, those in the world of science and medicine believed that they were doing everything possible to clean the health care environment. Best practices, including double cleanings, the newest wipes and solutions, have all become common place in most hospitals, yet infection rates have either remained the same or continued to increase while treatment has continued to become more problematic as antibiotic resistance increased.

Our discovery that the remaining 0.1% of MRSA bacteria following a conventional 3-log (99.9%) kill would regenerate to a full 5-log growth again in only five days (in some instances only 6 hours) was an eye opening discovery.  In-hospital proof that following the use of AsepticSure all of the bacteria were eliminated so there was no possibility of pathogen regeneration is now starting to be recognized as a turning point in what President Obama has declared as a “war against superbugs”.  When previously troublesome hospital rooms began going for very extended periods of time without another new infection, the paradigm shift began.  The cost benefit /ratio of AsepticSure implementation is compelling and the fact that there is no associated environmental damage or residual chemical left behind places AsepticSure in a league by itself.

Health care professionals in Canada are now realizing that for the first time a pathogen free room can be a reality, courtesy of AsepticSure.

Best regards,

Edwin G. Marshall
Chairman of the Board
Chief Executive Officer

 

 

Medizone AsepticSure Update

June 11, 2015

Dear Shareholders,

As a further update to our website posting of June 1st “AsepticSure® Progress Update,” the Alberta Ministry of Health has just confirmed that Alberta Health Services wishes to initiate the demonstration and equipment evaluation of AsepticSure at two major hospitals in September. The AsepticSure demonstrations will be held for two days each to allow for maximum attendance. One demonstration will be in Edmonton and the second in Calgary.

As noted in the same June 1st update, the Canadian National Infection Prevention and Control Conference is being held June 14th through June17th in Victoria, BC. In addition to the two presentations on AsepticSure efficacy by Professor Dick Zoutman at the conference, Dr. Michael Shannon and Professor Zoutman will host a private dinner sponsored by Medizone International. The invitees are senior infection control officers from across Canada. To date, we have 17 confirmations of acceptance.

We anticipate that these events will provide AsepticSure with a very significant, broad-based exposure to the larger Canadian medical decision makers at senior staff levels within both hospital management organizations and government.

It might also be noted that the recently elected Premier of Alberta, Rachel Notley, ran on a campaign that included promises for the reduction of Hospital Acquired Infections (HAI’s) in Alberta. She appears to be following through on her campaign promise.

Best regards,

Edwin G. Marshall
Chairman of the Board
Chief Executive Officer

AsepticSure Progress Update

AsepticSure®
Progress Update

June 1, 2015

Medizone International appears on the cusp of strong commercial breakthroughs. The superior efficacy of the AsepticSure process backed by its unassailable science is no longer in question. AsepticSure has proven to be the only hospital disinfection, cleaning technology that repeatedly eliminates all known pathogens in the space treated, demonstrating in-hospital the ability to break the hospital acquired infection (HAI) reinfection cycle. At the provincial level in Canada the medical community is starting to take serious notice.

New Canadian Initiatives:

A Provincial Ministry of Health in Canada has recently requested a demonstration of AsepticSure at two of its major hospitals in two different cities. It should be noted that these are not trials, but demonstrations of the systems operation. Dr. Shannon, along with our Canadian distributor Wood-Wyant, will be conducting these demonstrations. It has been communicated to Dr. Shannon from this Provincial Ministry of Health’s office that, “their search for a hospital disinfection technology suitable for adoption by the Province had been narrowed down to only one, AsepticSure.”

This is understandable in that recent peer-reviewed scientific literature has made it abundantly clear that the claims made for the disinfection capabilities of the ultra violet light systems have been grossly overstated. Straight hydrogen peroxide technologies have proven far more time consuming, toxic to the environment, and far less efficacious. Only AsepticSure has continued to demonstrate its 6-log efficacy while fitting nicely into normal hospital workflows. It is absolutely “green” in the sense that all medical equipment remains in the room during cleaning and the 100% disinfected space is then available for immediate occupancy the moment the door is opened following the disinfection cycle.

The Provincial Ministry’s purchasing agent is now playing a leading role in setting up these demonstrations, which are expected to take place in July following the Canadian National Infection Prevention and Control Conference in Victoria, BC. (This medical conference takes place June 14th through June 17, 2015.) At the conference, Queen’s University Professor Dr. Dick Zoutman, will be giving two talks and poster presentations on AsepticSure’s applications. They are titled, “Time, Cost Efficiency and Effectiveness of a Novel ozone-Hydrogen Peroxide Disinfection System (ARDS) During a Clostridium difficile Outbreak on an Acute Medical Unit” and “High Level Disinfection Effectiveness of a Novel Ozone-Hydrogen Peroxide Vapour Automated Room Disinfection System (ARDS) Against Non-Enveloped and Enveloped Viruses.”

Activities in Preparation for US Market Entry:

Preliminary planning has recently been initiated for demonstration of efficacy trials at two US hospitals. The intent of these trials is to replicate what has been achieved at Quinte Health Care’s Bellville General and Trenton Memorial Hospitals, breaking the isolation room re-infection cycle and stopping new HAI’s in their tracks. These trials will be conducted by a leading hospital contract cleaning service company working with the hospitals quality assurance personnel.

Assuming a successful trial outcome with results unequivocally demonstrating a greater than 6-log (>99.9999%) disinfection capability in all critical spaces (which essentially resets infection prone problem rooms as the safest rooms in the hospital), adoption of AsepticSure as their technology of choice is a distinct possibility. Until start dates are established and announced by the contractor, we will not be releasing any additional information.

This update may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

A Summary of peer-reviewed, published literature comparing the effectiveness of AsepticSure versus Xenex

It is of paramount importance to remember, that while there are other companies and technologies competing in our sector of business, only AsepticSure has demonstrated the ability to actually break the reinfection cycle in a healthcare setting. That is what sets us apart, as demonstrated at Belleville General Hospital in Ontario, Canada.

The demonstration at Belleville in which a ward that had averaged “one to two new MRSA infections a month” and has now gone more than a year without a new infection following a single AsepticSure disinfection, is strong evidence that when you kill 100% of the infective pathogen in a healthcare setting, you have broken the reinfection cycle. A response demonstrating this level of efficacy and effectiveness was simply not available until AsepticSure. This is the solution to a previously unsolvable problem.

We have demonstrated at our Innovation Park, Queen’s University Laboratories, that you must obtain 100% Kill to be effective. Working with MRSA, a 5-log sample was decontaminated by 3-log (99.9% kill). Set aside and simply observed, the remaining 0.1% of bacteria began to regenerate in 5 hours. In 5 days it had grown back to full strength! Only AsepticSure has demonstrated the ability to eliminate that 0.1% in both laboratory and real world hospital settings throughout an entire room!

Chart_AsepticSure_Versus_Xenex

References:

image

  1. Nerandzic MM, Thota P, Sankar TC, Jencson A, Cadnum JL, Ray AJ, Salata RA, Watkins RR, and Donskey CJ. Evaluation of a Pulsed Xenon Ultraviolet Disinfection System for Reduction of Healthcare-Associated Pathogens in Hospital Rooms. Infection Control & Hospital Epidemiology. 2015, Feb; 36:192-197.

  2. Zoutman D, Shannon M, Mandel A. Effectiveness of a novel ozone-based system for the rapid high-level disinfection of health care spaces and surfaces. American Journal of Infection Control. 2011 Dec; 39(10):873-879.